Cancer of the lung, breast, pancreas... We generally understand cancer based on where it started.
A so-called “organ” approach which, historically, became obvious when we were just beginning to treat cancers with surgery and radiotherapy, then later with chemotherapy.
This ultimately defined the way clinical trials are conducted and remains the glue for all medical treatment decisions to this day.
However, in recent decades, progress in research has taught us that certain tumors observed in very different organs are characterized by very similar anomalies and/or mechanisms, making this organ typology partly obsolete.
With the advent of targeted therapies and immunotherapies, which are based on a “trans-organ” approach, an urgent reflection on the classification of cancers is necessary, because it would allow better accessibility to…
This article is reserved for subscribers.
You have 85% left to discover.
Flash sale
Unlock all items immediately.
I ENJOY IT
Already subscribed?
Log in